Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02693938 · ClinicalTrials.gov registry record · NA
Blood Glucose Variability and Insulin Action During Menstrual Cycle in Females With Type 1 Diabetes
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 28
- Enrollment target
NCT02693938: Completed NA study, sponsored by Yale University.
NCT02693938 is a NA study that has completed, run by Yale University. The registered enrollment target is 28 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02693938, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 28 participants
- Enrollment target
Study Summary
This research study is designed to look at differences in responsiveness to the subcutaneous injection of a standardized dose of rapid-acting insulin analog and blood glucose variability during different phases of the menstrual cycle in females with type 1 diabetes (T1D).
Primary Outcome
The insulin glucodynamic action will be measured by the amount of dextrose infused during the study as previously described by DeFronzo. The primary outcome measure for the euglycemic clamp studies will be area under the glucose infusion rate (AUCGIR) that will be compared between luteal and follicular phases of menstrual cycle.
Interventions
- DEVICE Follicular Euglycemic clamp
- DEVICE Luteal Euglycemic clamp
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-11-13 |
| Est. Completion | 2020-02-07 |
| Phase | NA |
What the finished NCT02693938 record still lists
NCT02693938 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Follicular Euglycemic clamp is the first listed.
NCT02693938 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02693938 about?
NCT02693938 is a clinical study titled "Blood Glucose Variability and Insulin Action During Menstrual Cycle in Females With Type 1 Diabetes". This research study is designed to look at differences in responsiveness to the subcutaneous injection of a standardized dose of rapid-acting insulin analog and blood glucose variability during different phases of the menstrual cycle in females with type 1 diabetes (T1D).
What is the current status of trial NCT02693938?
This trial is currently completed. It is a NA study. The enrollment target is 28 participants. The study started on 2019-11-13. Estimated completion is 2020-02-07.
What interventions are being tested in trial NCT02693938?
The interventions under investigation include: Follicular Euglycemic clamp (DEVICE), Luteal Euglycemic clamp (DEVICE).
Who is sponsoring clinical trial NCT02693938?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02693938's enrollment target sits among peer trials
28 1704th of 2000 higher than 293 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI